JPRN-jRCTs031180063已完成1 期
A pilot phase I study of azacitidine for the first relapsed patients with infant acute lymphoblastic leukemia and MLL gene rearrangement - AZA-MLL-P16
Tomizawa Daisuke0 个研究点目标入组 1 人开始时间: 2018年12月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1
研究概览
简要总结
AZA-MLL-P16 trial is a single center phase I trial to evaluate a safety of hypomethylating agent azacytidine for children with relapsed MLL-rearranged B-ALL who was initially diagnosed at age younger than 2 years old. Total three patients were screened for registration between September 11, 2017 and March 31, 2022, but only one eligible patient could be registered. No DLT in DL1 was observed in that patient. However, DLT of azacitidine could not be evaluated due to an insufficient number of the patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 < 7age old（—）
- 性别
- All
入选标准
- •Patients should meet all the criteria listed below:
- •(1) Patients must be diagnosed as B-cell precursor acute lymphoblastic leukemia (ALL) with MLL gene rearrangement confirmed by FISH.
- •(2) Patients must be a first relapsed case.
- •(3) Patients must be less than 2 years old at the time of initial ALL diagnosis, and less than 7 years old at the time of consent.
- •(4) Patients must have received at least a single course of standard induction chemotherapy for relapsed ALL.
- •(5) All patients' parents or legal guardians must sign a written informed consent.
- •(6) Patients must have performance score (PS) of 0 to 3.
- •(7) Patients' peripheral blood cell count must be ANC 500/mcL or higher, after 48 hours or longer cessation of G-CSF.
- •(8) Patients must have sufficient organ function (liver, kidney, heart, lung) at the trial entry;
- •8-1. SpO2 96% or higher in room air, no abnormal findings in chest X-ray.
- •8-2. No abnormal ECG and UCG findings which require interventions.
- •8-3. AST and ALT value within 5 times of normal upper limit.
- •8-4. Serum bilirubin value within 2 times of normal upper limit.
- •8-5. Creatinine value within 2 times of normal upper limit.
排除标准
- •Patients should be excluded if either of the below criteria is met:
- •(1) Patients with uncontrollable infections.
- •(2) Patients with congenital heart disease that requires any interventions.
- •(3) Patients with somatic chromosomal abnormalities.
- •(4) Patients with active hemorrhage at study entry.
- •(5) Patients with CNS symptoms at study entry.
- •(6) Patients with other malignant diseases.
- •(7) Patients who cannot maintain peripheral blood platelet count of 10,000/mcL or higher with transfusions.
- •(8) Patients not eligible for the study entry decided by the primary/co-investigators of the study.
研究者
相似试验
已完成
1 期
Azacytidine and Valproic Acid in Patients With Advanced CancersAdvanced CancersNCT00496444M.D. Anderson Cancer Center69
已完成
1 期
A pilot phase I study of azacitidine for the first relapsed patients with infant acute lymphoblastic leukemia and MLL gene rearrangementChildren with first relapsed infant MLL gene rearrangement positive acute lymphoblastic leukemiaJPRN-UMIN000029275ational Center for Child Health and Development1
招募中
2 期
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaHodgkin's LymphomaNCT05355051M.D. Anderson Cancer Center24
Unknown
2 期
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyElderlyAcute Myeloid LeukemiaNCT00728520Kansas City Veteran Affairs Medical Center40
已完成
1 期
A trial of combined azacitidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia and myelodysplasia who relapse after allogeneic stem cell transplantatioTopic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: Leukaemia (acute myeloid)Acute monoblastic/monocytic leukaemiaCancerISRCTN98163167niversity of Birmingham (UK)31